抗氧化剂在弗里德赖希共济失调中的应用。
Antioxidant use in Friedreich ataxia.
作者信息
Myers Lauren, Farmer Jennifer M, Wilson Robert B, Friedman Lisa, Tsou Amy, Perlman Susan L, Subramony Sub H, Gomez Christopher M, Ashizawa Tetsuo, Wilmot George R, Mathews Katherine D, Balcer Laura J, Lynch David R
机构信息
Department of Neurology, University of Pennsylvania School of Medicine, USA.
出版信息
J Neurol Sci. 2008 Apr 15;267(1-2):174-6. doi: 10.1016/j.jns.2007.10.008. Epub 2007 Nov 7.
Abstract
Many antioxidants have been suggested as potential treatments for Friedreich ataxia, but have not been tested in clinical trials. We found that a majority of patients in our cohort already use such antioxidants, including idebenone, which is not available at a pharmaceutical grade in the United States. Younger age, cardiomyopathy and shorter GAA repeat length were independent predictors of idebenone use, but no factors predicted use of other antioxidants. This confirms that non-prescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia.
摘要
许多抗氧化剂已被提议作为治疗弗里德赖希共济失调的潜在疗法，但尚未在临床试验中进行测试。我们发现，我们队列中的大多数患者已经在使用此类抗氧化剂，包括艾地苯醌，而该药物在美国没有药用级别的产品。年龄较小、患有心肌病以及GAA重复长度较短是使用艾地苯醌的独立预测因素，但没有因素能预测其他抗氧化剂的使用情况。这证实了非处方抗氧化剂的使用是现有和新型弗里德赖希共济失调药物正式试验的一个主要混杂因素。
相似文献
1
Antioxidant use in Friedreich ataxia.
J Neurol Sci. 2008 Apr 15;267(1-2):174-6. doi: 10.1016/j.jns.2007.10.008. Epub 2007 Nov 7.
2
Exonic deletions of FXN and early-onset Friedreich ataxia.
Arch Neurol. 2012 Jul;69(7):912-6. doi: 10.1001/archneurol.2011.834.
3
Idebenone in patients with Friedreich ataxia.
Neurosci Lett. 2001 Jun 29;306(3):169-72. doi: 10.1016/s0304-3940(01)01892-4.
4
Pharmacological treatments for Friedreich ataxia.
Cochrane Database Syst Rev. 2016 Aug 30;2016(8):CD007791. doi: 10.1002/14651858.CD007791.pub4.
5
Clinical experience with high-dose idebenone in Friedreich ataxia.
J Neurol. 2009 Mar;256 Suppl 1(0 1):42-5. doi: 10.1007/s00415-009-1008-x.
6
Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).
Am Heart J. 2011 Mar;161(3):639-645.e1. doi: 10.1016/j.ahj.2010.10.038. Epub 2011 Jan 31.
7
Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia.
Arch Phys Med Rehabil. 2010 Jul;91(7):1044-50. doi: 10.1016/j.apmr.2010.04.007.
8
Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
Arch Neurol. 2005 Apr;62(4):621-6. doi: 10.1001/archneur.62.4.621.
9
Antioxidants and other pharmacological treatments for Friedreich ataxia.
Cochrane Database Syst Rev. 2012 Apr 18(4):CD007791. doi: 10.1002/14651858.CD007791.pub3.
10
Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.
Lancet Neurol. 2007 Oct;6(10):878-86. doi: 10.1016/S1474-4422(07)70220-X.
引用本文的文献
1
Friedreich ataxia: clinical features and new developments.
Neurodegener Dis Manag. 2022 Oct;12(5):267-283. doi: 10.2217/nmt-2022-0011. Epub 2022 Jun 29.
2
Thioredoxin and Glutaredoxin Systems as Potential Targets for the Development of New Treatments in Friedreich's Ataxia.
Antioxidants (Basel). 2020 Dec 10;9(12):1257. doi: 10.3390/antiox9121257.
3
Role of frataxin protein deficiency and metabolic dysfunction in Friedreich ataxia, an autosomal recessive mitochondrial disease.
Neuronal Signal. 2018 Nov 2;2(4):NS20180060. doi: 10.1042/NS20180060. eCollection 2018 Dec.
4
Milestones in Friedreich ataxia: more than a century and still learning.
Neurogenetics. 2015 Jul;16(3):151-60. doi: 10.1007/s10048-015-0439-z. Epub 2015 Feb 8.
5
Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.
World J Methodol. 2014 Dec 26;4(4):197-218. doi: 10.5662/wjm.v4.i4.197.
6
Redox processes in neurodegenerative disease involving reactive oxygen species.
Curr Neuropharmacol. 2012 Dec;10(4):289-302. doi: 10.2174/157015912804143487.
7
Drug development for rare mitochondrial disorders.
Neurotherapeutics. 2013 Apr;10(2):286-306. doi: 10.1007/s13311-013-0179-4.
8
Childhood ataxia: clinical features, pathogenesis, key unanswered questions, and future directions.
J Child Neurol. 2012 Sep;27(9):1095-120. doi: 10.1177/0883073812448840. Epub 2012 Aug 1.
9
Cardiac involvement in hereditary ataxias.
J Child Neurol. 2012 Sep;27(9):1174-8. doi: 10.1177/0883073812449382. Epub 2012 Jul 4.
10
Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice.
PLoS One. 2011;6(12):e28855. doi: 10.1371/journal.pone.0028855. Epub 2011 Dec 19.
本文引用的文献
1
Changes in use of herbs and dietary supplements (HDS) among clinicians enrolled in an online curriculum.
BMC Complement Altern Med. 2007 Jun 12;7:21. doi: 10.1186/1472-6882-7-21.
2
Use of herbal/natural supplements according to racial/ethnic group.
J Altern Complement Med. 2006 Jul-Aug;12(6):555-61. doi: 10.1089/acm.2006.12.555.
3
Measuring Friedreich ataxia: complementary features of examination and performance measures.
Neurology. 2006 Jun 13;66(11):1711-6. doi: 10.1212/01.wnl.0000218155.46739.90.
4
Patterns of dietary supplement usage in demographically diverse older people.
Altern Ther Health Med. 2005 May-Jun;11(3):48-53.
5
Assembly of human frataxin is a mechanism for detoxifying redox-active iron.
Biochemistry. 2005 Jan 18;44(2):537-45. doi: 10.1021/bi048459j.
6
Friedreich ataxia: the oxidative stress paradox.
Hum Mol Genet. 2005 Feb 15;14(4):463-74. doi: 10.1093/hmg/ddi042. Epub 2004 Dec 22.
7
Iron-sulfur protein maturation in human cells: evidence for a function of frataxin.
Hum Mol Genet. 2004 Dec 1;13(23):3007-15. doi: 10.1093/hmg/ddh324. Epub 2004 Oct 27.
8
Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring.
Neurology. 2003 May 27;60(10):1679-81. doi: 10.1212/01.wnl.0000068549.52812.0f.
9
Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial.
Neurology. 2003 May 27;60(10):1676-9. doi: 10.1212/01.wnl.0000055872.50364.fc.
10
Use of complementary alternative medicine in patients admitted to internal medicine wards.
Int J Clin Pharmacol Ther. 2002 Dec;40(12):539-47. doi: 10.5414/cpp40539.
Zotero 插件